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Methicillin-resistant Staphylococcus aureus contributes significantly to cost, morbidity, and mortality due to infectious disease. We
surveyed community-associated MRSA isolates to determine which strains were present within anatomical sites of interest. The
most likely sources of MRSA among anatomic sites swabbed were wounds followed by the nasal cavity. The USA 300 MRSA strain
was most commonly isolated among wound infections while nasal swabs largely yielded USA 100 MRSA. The frequency of isolation
of USA 100 amongst community-associated strains is clinically significant as this strain is often correlated with invasive disease,
exhibits broad antibiotic resistance, and has been considered to be hospital associated. The potential of USA 100 to cause serious
disease and the frequency of its isolation suggest an important reservoir for opportunistic infection. These data demonstrate that
MRSA epidemic clones are widespread among the community.

1. Background
An epidemic community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) strain designated USA
300 has been isolated from infections in several locations
within the United States [1–9]. The USA 300 epidemic
clone has been associated with serious community-acquired
disease, often in patients who lack the traditional risk factors
for MRSA infections including hospitalization, concurrent
disease, and intravenous drug use [10–12]. USA 300 carries
the Panton-Valentine leukocidin (PVL) toxin genes among
other virulence factors, which may contribute to its ability
to cause serious disease including primary skin infections
and necrotizing pneumonia. Recently, USA 300 has also
been identified as a common cause of community-associated
infections in Florida [9].
MRSA infections are a major public health concern
due to the associated morbidity, mortality, cost of care,
and limited treatment options [13]. Primary skin infections
caused by USA 300 can be spread readily among groups
engaging in contact sports [1, 6]. Diseases such as necrotizing

pneumonia caused by PVL-positive strains, such as USA
300, have a high mortality rate as demonstrated by a study
of 23 patients in which 61% of those patients succumbed
to the disease [14]. The cost of care for infections caused
by methicillin-resistant strains of S. aureus is approximately
twice that of infections caused by susceptible S. aureus
strains primarily due to greater inpatient hospital costs [15].
Most patients with skin infections are treated with trimethoprim/sulfamethoxazole alone or in combination with a second drug such as cephalexin and/or clindamycin. However,
recent data suggests that resistance to these antimicrobials
among community MRSA is increasing [16].
The Centers for Disease Control and Prevention (CDC)
has applied the designation USA 100-800 and USA 10001100 to MRSA strains commonly found in the United States
[7]. Pulsotypes for epidemic clones historically associated
with hospital-associated infections include USA 100, USA
200, USA 500, USA 600, and USA 800 [7]. The epidemic
clone USA 100 is associated with invasive disease in hospitalized patients and in each case where MRSA has become
resistant to vancomycin, resulting in VRSA, USA 100 has

2
been the strain involved [17]. The USA 200 clone is most
notable for its ability to cause toxic shock as it possesses the
TSST-1 or toxic shock toxin genes [18]. Interestingly, data
on nasal carriage of USA 200 demonstrated a significant
drop in percentage from the 2001-2002 to the 2003-2004
time periods for reasons that are unknown [19]. The USA
500 epidemic clone is most notable as the progenitor strain
of USA 300. USA 500 lacks the PVL (Panton-Valentine
leukocidin) genes and mobile genetic elements which have
likely contributed to the high virulence and transmissibility
seen in the USA 300 strains [20]. However, unlike USA
300 isolates, USA 500 isolates are more likely to be multiply resistant which may contribute to their success in the
healthcare environment [19]. USA 600 has been noted among
hospital isolates but has not, until recently, been reported as
a cause of serious disease. However, a recent study reported
a 60% mortality rate associated with blood stream infections
caused by USA 600 [21]. The final hospital-associated isolate,
USA 800, is highly related to USA 100 and most notable
for its increased resistance to daptomycin [22]. Pulsotypes
for epidemic clones historically associated with communityonset disease included USA 300 discussed above and the
closely related USA 400 isolate. Although it is as a well-known
community-associated strain worldwide and has historically
caused serious disease in the United States, USA 400 seems
to have been outcompeted by USA 300 [23]. The USA 1000
isolates occur infrequently and are usually associated with
wound infections in persons who abuse drugs [7]. USA 1100
phenotype is associated with localized occurrences such as an
outbreak of furunculosis reported in Alaska [7, 24]. Finally,
USA 700 is associated with both community and hospital
onset disease which is rarely serious.
We have previously identified the USA 300 epidemic
clone among CA-MRSA isolates collected in both Florida and
Washington States [9]. We identified 111 USA 300 isolates
among 260 CA-MRSA collected in Florida through the use of
pulsed-field gel electrophoresis (PFGE) which is considered
the gold standard for S. aureus molecular epidemiology [7,
25–28]. Our study included isolates obtained from wounds,
blood, sputa, nasal swabs, and other anatomical sites. Similar
to other studies, we demonstrated that 98 of the 111 Florida
USA 300 isolates were collected from wound samples [1–3, 6–
10]. In the present study, we have expanded the total number
of isolates collected in Florida to 291 to assess the presence
of the known United States MRSA epidemic clones among a
collection of Florida’s CA-MRSA.

2. Methods
A total of 291 CA-MRSA isolates collected in Florida and
submitted to the Florida Department of Health (FL DOH),
Bureau of Laboratories in Tampa, were used in this study.
Community-associated isolates were defined as those collected from outpatient services or within 48 hours of hospitalization. Isolates were classified as MRSA and communityassociated by area hospital laboratories serving primarily central Florida including Tampa and Orlando. Some laboratories
submitted more than one isolate per patient from multiple
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body sites. We confirmed that these isolates were identical
strains and therefore only one per patient is included in this
study. Control strains used for the PFGE were as follows:
USA 100-USA 800 (NRS282-287, NRS123, and NRS22) and
USA 1000-1100 (NRS483-4) were obtained from NARSA
(http://www.narsa.net/). The PFGE marker strain, NCTC
8325 (NRS77) was used as a control on all PFGE gels and was
also obtained from NARSA. The identification of all isolates
as S. aureus and their antibiotic resistance was confirmed as
previously reported [9].
PFGE was performed as previously reported for enterococcal isolates [29] with the following changes for S. aureus.
Overnight cultures of S. aureus were grown in BBL Trypticase
Soy Broth (Becton Dickinson, Sparks, MD). Lysostaphin
(number L7386, Sigma, St. Louis, MO) was added to the EClysis buffer at a concentration of 3 U/mL and plugs were lysed
for five hours at 37∘ C, followed by overnight incubation in
ESP solution at 50∘ C. Plugs were digested in SmaI overnight,
melted at 69∘ C for 10 mins, and loaded onto a 1 Seakem
Gold (Cambrex BioScience, Rockland, ME) gel. PFGE was
performed using a DR-II CHEF Mapper (Bio-Rad, Hercules,
CA) using the following parameters: 200 V, 14∘ C, 5.3 s initial
switch, 34.9 s final switch, and 20 hrs run time. Data was
analyzed using BioNumerics (Applied Maths, St-Martens,
Belgium).
Dendrograms were derived from the unweighted pair
group method (UPGMA) using arithmetic averages and
based on Dice coefficient.

3. Results
PFGE was performed on a total of 291 CA-MRSA isolates collected in Florida. The resulting patterns were imported into
the BioNumerics database and dendrograms were created as
described. The majority of the isolates in our collection were
assigned pulsotypes consistent with one of the previously
identified epidemic clones.
3.1. USA 300 Epidemic Clone. Approximately half of the
isolates tested possessed pulsotypes consistent with the USA
300 epidemic clone. The majority of these isolates were
identified using the dendrograms generated by BioNumerics.
Phylogenetic comparison was possible because the DNA
fingerprints of these isolates were identical to the USA 300
control strain pulsotype (Figure 1). However, a number of
previously unidentified USA 300 isolates were elucidated
by visual comparison to recently published USA 300 DNA
fingerprints for which there are no control strains available
[23]. In this case, since there are no control strains available,
it is impossible to perform phylogenetic comparison using
BioNumerics. These newly recognized USA 300 isolates
differed from the control strain by no more than two bands
and are therefore considered identical strains (Figure 1) [30].
USA 300 accounted for 145 or nearly 50% of the CA-MRSA
isolates collected in Florida, as compared to 43% of isolates
in our earlier study [9]. The vast majority of these strains,
126 or 87%, were obtained from wound infections (Table 1,
Figure 3), consistent with our earlier study [9]. The USA 300
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Table 1: Summary of results for all isolates.

Source of isolates
Blood
Nose
Sputum
Wound
Other
Total

USA
100

USA
300

10
42
0
27
6
85

1
15
2
126
1
145

Number of isolates for each pulsotype
USA
USA
USA
USA
500
600
800
1000
0
1
0
0
0
1

0
1
0
0
0
1

0
1
2
0
0
3

0
6
2
2
0
10

Sporadic

Total number of isolates from source

5
19
11
5
6
46

16
85
17
160
13
291

Dice (Opt: 1.00%)(Tol 1.0%-1.0%)(H > 0.0% S > 0.0%) [0.0%–100.0%]
PFGE
PFGE
60

70

80

90

100
CBD0834

Wound

FL DOH

CBD0908

Wound

FL

CBD0662

Sputum

FL

CBD1066

NARSA

USA 300

CBD0915

Wound

FL

Figure 1: BioNumerics analysis of USA 300 epidemic clones: the NARSA USA 300 control strain (CBD1066) was used to identify most of
the USA 300 epidemic clones in our collection.
Dice (Opt: 1.00%)(Tol 1.0%-1.0%)(H > 0.0% S > 0.0%) [0.0%–100.0%]
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Figure 2: BioNumerics analysis of USA 100 epidemic clones: the NARSA USA 100 control strain (CBD1064) was used to identify most of the
USA 100 epidemic clones in our collection.

epidemic clone was also rarely seen among isolates from
blood, nose, sputa, and other clinical sites (Table 1, Figure 3).
3.2. USA 100 Epidemic Clone. In contrast to publications
suggesting that USA 100 epidemic clone is a hospital-acquired
strain, isolates closely related to the USA 100 control strain
accounted for 29% of the CA-MRSA isolates collected in
Florida (Table 1) [7]. A total of six different pulsotypes, which
differed by one to two bands from the USA 100 control
strain, were identified among the Florida isolates (Figure 2).
While nearly 32% of these strains were cultured from wound
infections, the majority of the isolates (49%) were from nasal
swabs (Figures 2 and 3).

3.3. Other Pulsotypes Identified among CA-MRSA Isolates.
PFGE analysis identified one isolate each with 100% identity
to the USA 500 and USA 600 control strains (Table 1).
BioNumerics analysis also demonstrated three isolates with
100% identity to the USA 800 control strain (Table 1). Further
analysis of these isolates was not performed as they were rare
among Florida CA-MRSA. Interestingly, 10 isolates matched
by visual comparison to the published PFGE pattern for a
newly described epidemic clone, USA 1000 (Table 1) [31]. The
epidemic clones USA 200, USA 400, and USA 1100 were not
present among the Florida isolates. The remaining isolates
were categorized as sporadic as they possess pulsotypes that
are unique to each isolate with no known match.

4
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Total number of isolates
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Figure 3: Total number of CA-MRSA isolates categorized by
isolation site: CA-MRSA isolates collected from blood, nose, sputa,
wound, and other clinical sites were characterized by PFGE.

4. Discussion
In the present study we demonstrate that the USA 300 epidemic clone is well established in the state of Florida, accounting for nearly 50% of all CA-MRSA isolates collected. Consistent with other studies [10–12], we demonstrated that USA
300 is the most prominent strain among isolates collected
from wound infections. These data suggest that the USA
300 clone is particularly well adapted for spreading in the
community environment. The potential of this highly virulent
strain to cause disease in otherwise healthy individuals, along
with its propensity to spread rapidly in the community
environment, is a cause for concern.
Historically, MRSA isolates were well known to be multidrug resistant. And, in addition to 𝛽-lactam resistance,
hospital-acquired isolates are frequently resistant to other
classes of antibiotics. Therefore, treatment of MRSA infections has often involved the use of vancomycin. The use
of vancomycin to treat MRSA infections provides selective
pressure for the emergence of vancomycin-resistant S. aureus
(VRSA) and vancomycin-intermediate S. aureus (VISA).
However, the USA 300 epidemic clone, while being resistant
to oxacillin, lacks the antibiotic resistance of the hospital
strains. In a study of 187 USA 300 isolates, 100% were susceptible to chloramphenicol, gentamicin, linezolid, quinupristindalfopristin, and trimethoprim-sulfamethoxazole [23].
The large number of USA 100 isolates identified among
the Florida CA-MRSA in the present study was unexpected
since this strain was previously characterized as a hospitalacquired isolate [7]. Furthermore, national surveys of nasal
colonization have reported USA 200 as the most common
nasal colonizer [19]. This finding would suggest that the USA
100 clone has moved from the hospital to the community
environment, but it has not been associated with any disease
etiology. The majority of the USA 100 strains herein were
isolated from nasal swabs, suggesting that this strain may
be involved in colonization as opposed to disease. Further
evidence for a role in colonization may be the fact that these
isolates do not carry the PVL genes, suggesting that they lack
the virulence of other MRSA epidemic clones. Regardless,

many USA 100 isolates were cultured from wound sites
(Table 1) possibly because most MRSA carriers will autoinfect
themselves with the same isolates that they harbor [32–34].
Therefore, periodic monitoring of the rates of nasal carriage,
followed by appropriate treatment to eliminate strains, may
be required to stop the spread of the epidemic clone in the
community environment. Although the isolates used in this
study were collected from individuals in the community,
it is unknown if these persons have a history of prior
hospitalization. Regardless, the USA 100 strain has become
well established in the community environment.
As expected, most of the remaining epidemic clones,
including USA 200 and USA 500, were absent or present
only in small numbers in the community. However, a recently
described clone, USA 1000, was identified in 10 isolates in
our study. This clone is unique in that it is rarely involved
in colonization or disease except among intravenous drug
users [31]. Consultations with physicians who treated these
infections confirmed that in each case a history of drug use
was present (personal communication). This unusual strain
should therefore be considered as a possible cause of infection
in this high-risk group. Similar to USA 300, USA 1000 is
resistant to 𝛽-lactam antibiotics but many other treatment
options remain.

5. Conclusions
The present study has demonstrated that the highly virulent
USA 300 epidemic CA-MRSA strain is widespread in Florida.
Florida healthcare practitioners should consider CA-MRSA
as a possible cause of cases of primary skin infections
including necrotizing fasciitis and as a cause of necrotizing
pneumonia, especially among otherwise healthy individuals.
This study has also demonstrated that the USA 100 isolate,
commonly considered a hospital-acquired strain, is well
established in the community in Florida. Treatment of this
strain is complicated as it is multidrug resistant and sensitivity
data are required. The practice of prescreening patients upon
admission in some Florida hospitals followed by MRSA
treatment is highly recommended to prevent invasive disease
caused by USA 100.

6. Limitations of the Study
A limitation of this study was the use of blinded samples,
required due to the nature of the funding used, wherein
the clinical information from the patients was not available.
The number and nature of isolates forwarded for analysis
were at the discretion of the submitting laboratories within
the guidelines generally accepted for community associated
infections as described. The role of nosocomial spread and
exact geographic location within the state of Florida of the
isolates is therefore unknown to the authors of this study.
Future study should include the geographic information,
patient history, and powered study design to estimate the
incidence of these isolates among Florida MRSA.
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